Inhibition of the renal SGLT2 transporter has proven to be an effective therapeutic interventionto reduce plasma glucose levels and HbA1c in type 2 diabetic patients. The glycemic-loweringefficacy of the SGLT2 inhibitors results from two distinct mechanisms: (i) induction ofglucosuria, which amounts to ~70-90 grams per day and (ii) amelioration of glucotoxicity leadingto increased insulin sensitivity in muscle and improved beta cell function (JCI 124:509-514,2014).
A Collaboration of the San Antonio Bioscience and Medical Research Community
A first-of-its-kind initiative between public and private sector to catalog and highlight Bioscience research in the city of San Antonio and the surrounding areas.
